Welcome to our dedicated page for Trulieve Cannabis SEC filings (Ticker: TCNNF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trulieve Cannabis Corp. (TCNNF) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and periodic financial statements. As a British Columbia–incorporated issuer with operations in the United States, Trulieve files with the Securities and Exchange Commission, offering detailed insight into its financial condition, capital structure, and material events.
Trulieve’s recent Form 8-K filings illustrate how the company uses SEC reports to communicate significant developments. For example, the company has filed 8-Ks describing commitments for, and the issuance of, 10.5% senior secured notes due 2030, including key terms such as interest rate, maturity, security (a pledge of shares of a restricted subsidiary), optional redemption provisions, and covenants that limit additional indebtedness, restricted payments, asset sales, and affiliate transactions. These filings also explain that net proceeds are intended for capital expenditures and general corporate purposes.
Other 8-Ks cover topics such as the redemption and planned delisting of 8.0% senior secured notes due 2026, and the release of quarterly financial results. In these documents, Trulieve reports revenue, gross profit, net loss, cash flow from operations, and non-GAAP measures, along with condensed balance sheets and cash flow statements. Investors can use these filings to analyze trends in retail revenue, operating expenses, leverage, and liquidity.
Through Stock Titan, users can view Trulieve’s 10-Q and 10-K filings when available, which provide more comprehensive discussions of risk factors, tax matters (including Section 280E and uncertain tax positions), and segment performance. The platform’s AI-powered summaries help explain complex sections, such as debt indentures, covenant packages, and non-GAAP reconciliations, so readers can quickly grasp what changes in each filing may mean for Trulieve’s operations and capital structure. Real-time updates ensure that new Forms 4, 8-K, 10-Q, and 10-K are surfaced as they are posted to EDGAR.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported several equity-related transactions. On March 13, 2026, she received a grant of 155,561 stock options with an exercise price of $6.40 per share, expiring on March 13, 2033. She was also granted 218,750 restricted stock units (RSUs), each representing one subordinate voting share; 50% vest on December 1, 2027 and 50% on December 1, 2028.
On March 3, 2026, 8,200 Multiple Voting Shares were converted into 820,000 Subordinate Voting Shares on a one-for-100 basis. Following these transactions, she holds 3,175,920 subordinate voting shares directly. Footnotes state she also holds 151,667 Multiple Voting Shares directly, 9,867 Multiple Voting Shares through Traunch IV LLC (with beneficial ownership disclaimed except for her pecuniary interest), and stock options vested as of December 1, 2025 to acquire 1,152,960 subordinate voting shares.
Trulieve Cannabis Corp. President Jason Pernell received equity awards in the form of restricted stock units (RSUs) and stock options. On March 13, 2026, he was granted 41,668 stock options, each allowing him to buy one subordinate voting share at an exercise price of $6.40 per share, expiring on March 13, 2033. The option vests in three equal annual installments on December 1, 2026, December 1, 2027, and December 1, 2028.
On the same date, he also acquired 58,594 subordinate voting shares as a grant of RSUs, with no cash purchase price. Each RSU represents one subordinate voting share. Half of these RSUs will vest on December 1, 2027, and the remaining half on December 1, 2028. Following the RSU grant, his direct holdings of subordinate voting shares increased to 581,795 shares. Footnotes state that separate trusts associated with him also hold 22,635 and 22,636 Multiple Voting Shares, which are convertible into an aggregate of 4,527,100 subordinate voting shares.
Trulieve Cannabis Corp. reported an equity compensation grant to executive Christine Ann Hersey, Chief Corporate Affairs & Strategy. She received 41,668 stock options with an exercise price of $6.40 per share, expiring on March 13, 2033. These options vest in three equal annual installments on December 1, 2026, December 1, 2027, and December 1, 2028.
Hersey also received 58,594 restricted stock units (RSUs), each representing one subordinate voting share. Half of these RSUs vest on December 1, 2027, and the remaining half on December 1, 2028. Following the RSU grant, she directly holds 143,767 subordinate voting shares. These are compensation-related awards rather than open‑market purchases.
Trulieve Cannabis Corp. Chief Production Officer Kyle Landrum received new equity awards as compensation. He was granted options to buy 41,668 subordinate voting shares at an exercise price of $6.40 per share, expiring on March 13, 2033. These options vest in three equal annual installments on December 1, 2026, December 1, 2027, and December 1, 2028.
Landrum also received 58,594 restricted stock units, each representing one subordinate voting share. Half of these RSUs vest on December 1, 2027 and the remaining half on December 1, 2028. Following the RSU grant, he directly owns 258,776 subordinate voting shares.
Trulieve Cannabis Corp. Chief Financial Officer Jan Reese reported receiving new equity compensation awards. Reese was granted options to buy 41,668 subordinate voting shares at an exercise price of $6.4000 per share, expiring on March 13, 2033. These options vest in three equal annual installments on December 1, 2026, December 1, 2027, and December 1, 2028, and 41,668 options are shown as held after the grant. Reese also received 58,594 restricted stock units, each representing one subordinate voting share. According to the award terms, 50% of these RSUs vest on December 1, 2027 and the remaining 50% vest on December 1, 2028, with 58,594 shares reported as held following this grant. These are compensation-related acquisitions, not open‑market purchases or sales.
Trulieve Cannabis Corp. reported that Chief Legal Officer Eric Powers received equity-based compensation awards. He was granted stock options for 41,668 subordinate voting shares at an exercise price of $6.40 per share, expiring on March 13, 2033, vesting in three equal annual installments starting December 1, 2026.
Powers also received 58,594 restricted stock units, each representing one subordinate voting share. Half of these RSUs vest on December 1, 2027, and the remaining half on December 1, 2028. Following these awards, he directly owns 245,311 subordinate voting shares, and 1,000 additional shares are held indirectly by his spouse.
Trulieve Cannabis Corp. Chief Technology Officer Nilyum Jhala reported equity compensation awards. Jhala received 58,594 restricted stock units, each representing one subordinate voting share, with 50% vesting on December 1, 2027 and 50% on December 1, 2028.
Jhala was also granted a stock option for 41,668 subordinate voting shares at an exercise price of 6.40 per share, vesting in three equal annual installments on December 1, 2026, December 1, 2027, and December 1, 2028, and expiring on March 13, 2033. Following these awards, Jhala directly owns 239,254 subordinate voting shares and has indirect beneficial ownership of 7,000 shares held by a spouse.
Walsh Brett R. reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. reported that Chief Accounting Officer Brett R. Walsh received an equity grant in the form of 28,711 restricted stock units, each representing one subordinate voting share. Half of these RSUs vest on December 1, 2027, and the other half on December 1, 2028. Following this compensation-related award, Walsh directly holds 140,305 subordinate voting shares.
Thronson Susan reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. director Susan Thronson received an equity award in the form of restricted stock units (RSUs). The grant covers 23,438 RSUs, each representing a contingent right to receive one Trulieve subordinate voting share at no cash cost.
The RSUs vest on the earliest of the end of her board service, a change of control of Trulieve, or December 1, 2032. Following this award, Thronson holds 64,543 subordinate voting shares directly and 9,740 shares indirectly through the Thronson Family Trust UA.
MILLNER THOMAS L reported acquisition or exercise transactions in this Form 4 filing.
Trulieve Cannabis Corp. director Thomas L. Millner received an equity compensation award in the form of 23,438 subordinate voting share units on March 13, 2026. These units were granted at no cash cost to him and increase his direct holdings to 72,543 shares.
The award is structured as restricted stock units (RSUs), each representing a contingent right to receive one Trulieve subordinate voting share. The RSUs will vest upon the earliest of the end of Millner’s board service, a change of control at Trulieve, or December 1, 2032, tying his compensation to long-term company performance.